NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Markets for Emerging Pharmaceutical Technologies
http://www.reportlinker.com/p0492944/Markets-for-Emerging-Pharmaceutical-Technologies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
REPORT HIGHLIGHTS
*
As a segment, therapeutic vaccines recorded $19.3 billion in 2010, a figure that is expected to grow to $31.9 billion by 2015, demonstrating a compound annual growth rate (CAGR) of 10.6%.
*
Treatment for infectious disease continues to advance, growing from a 2010 figure of $86.5 billion to $116 billion by 2015, a compound annual growth rate (CAGR) of 6.1%. Large and important areas including Hepatitis and HIV/AIDS will drive this increase.
*
Biomarkers, as an enabling element within drug development, will experience explosive growth, increasing from a current $13.5 billion to $33.3 billion in 2015, a 19.8% compound annual growth rate (CAGR) for the forecast period. The increased application of biomarkers in nonclinical, clinical and point of care areas in addition to stratifying patient populations to increase targeted applications of medicine will drive the increase.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of emerging pharmaceutical technologies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the emerging technologies segment. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.
The emerging technologies therapeutic market presents the largest of all opportunities in representative disease subsegments. Market growth has been spurred by the introduction of differentiated therapies due to novel mechanisms of action, such as P2Y12 inhibitors and factor Xa inhibitors.
This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets, by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the FDA, and those products expected to be approved within the forecast period are projected. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For all areas, including the very large markets segments such as infectious disease and cardiovascular, specific mechanisms of action are discussed in detail.
The report includes analysis of leading and emerging competitors in the current worldwide emerging technologies market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.
Market figures are based on revenues at the manufacturers' level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.
Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the Emerging Technologies market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease subsegment.
Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician's prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented are on a global basis, unless specifically noted.
INTENDED AUDIENCE
This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the Emerging Technologies market, its products, its industry participants and its future.
The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:
* Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D
* Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study
* Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis
* Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.
The overall emerging technologies sector is comprised of a variety of fast growing and independent segments. For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment. Within each subsection, there is a detailed forecast for each driving mechanism, or relevant area of growth.
Information to prepare this report was obtained from participating and emerging companies in the emerging technologies area; American Heart Association; the National Heart, Lung, and Blood Institute; articles published in medical journals such as American Heart Journal, Circulation, Journal of Emerging Technologies Pharmacology, Lancet, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks; and others. Population estimates are based on those reported by the international data base of the U.S. Census Bureau.
Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.
CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY AND INFORMATION SOURCES 3
RELATED REPORTS 4
BCC ONLINE SERVICES 4
DISCLAIMER 5
CHAPTER TWO: SUMMARY 6
SUMMARY TABLE GLOBAL EMERGING TECHNOLOGIES
FORECAST BY AREA, THROUGH 2015 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL EMERGING TECHNOLOGIES
FORECAST BY AREA, 2009-2015 ($ MILLIONS) 7
SUMMARY (CONTINUED) 8
CHAPTER THREE: THERAPEUTIC VACCINES 9
OVERVIEW 9
TABLE 1 GLOBAL MARKET FOR THERAPEUTIC VACCINES,
THROUGH 2010 ($ MILLIONS) 9
KEY EVENTS IN THE THERAPEUTIC VACCINE MARKET 10
EXPANDING SEGMENT: PROPHYLACTIC CANCER
VACCINES 10
VACCINE OPPORTUNITY SLACKENING DUE TO
OVERCAPACITY 10
CELL CULTURE AND ADJUVANT TECHNOLOGY
ENABLE THERAPEUTIC VACCINES 11
TABLE 2 MARKET FORECAST FOR THERAPEUTIC VACCINES,
THROUGH 2015 ($ MILLIONS) 11
LEADING VACCINE BRANDS 12
TABLE 3 LEADING VACCINE BRANDS, THROUGH 2010 ($
MILLIONS) 12
HEPATITIS VACCINES 12
PRODUCTS SUMMARY 12
TABLE 4 MARKET FOR LEADING VACCINES: HEPATITIS
SEGMENT, THROUGH 2010 ($ MILLIONS) 13
MARKET DYNAMICS 13
INFLUENZA VACCINES 14
TABLE 5 MARKET FOR LEADING VACCINES: INFLUENZA
SEGMENT, THROUGH 2010 ($ MILLIONS) 14
H1N1 SWINE FLU 15
MARKET DYNAMICS 15
PNEUMONIA VACCINES 16
MARKET DYNAMICS 16
MENINGITIS VACCINES 17
TABLE 6 MARKET FOR LEADING VACCINES: MENINGITIS
SEGMENT, THROUGH 2010 ($ MILLIONS) 17
MARKET DYNAMICS 18
OTHER VACCINES 18
HUMAN PAPILLOMAVIRUS (HPV) VACCINES 18
MARKET DYNAMICS 18
Market Dynamics (Continued) 19
EMERGING TARGETS IN THERAPEUTIC VACCINES 20
THE NEW VACCINE STRATEGY: THERAPEUTIC
VACCINES 20
Therapeutic Vaccines with Traditional Strategies 20
Antigen/Whole Cell Vaccines 20
Therapeutic Vaccines with Novel and Advanced
Strategies 20
Dendritic Cell Vaccines 20
Cytolytic Viral Vaccines 21
DNA Vaccines 21
AFFiTOPE/AFFiTOME 22
Beta Amyloid 22
Somatostatin GHRH 23
Plasmid Encorders 24
Telomerase Endogenous Reverse Transcriptase (TERT) 25
PIPELINE ANALYSIS 26
INTRODUCTION 26
RECENTLY APPROVED PRODUCTS 26
Menveo 26
TABLE 7 PRODUCT PROFILE SUMMARY: MENVEO 26
Menveo (Continued) 27
Prevnar 13vPnC 28
TABLE 8 PRODUCT PROFILE SUMMARY: PREVNAR 13VPNC 28
Prevnar 13vPnC (Continued) 29
Cervarix 30
TABLE 9 PRODUCT PROFILE SUMMARY: CERVARIX 30
Synflorix 31
TABLE 10 PRODUCT PROFILE SUMMARY: SYNFLORIX 31
Synflorix (Continued) 32
Ixiaro/Jespect 33
TABLE 11 PRODUCT PROFILE SUMMARY: IXIARO/JESPECT 33
Provenge 34
TABLE 12 PRODUCT PROFILE SUMMARY: PROVENGE 34
Provenge (Continued) 35
Provenge (Continued) 36
DEVELOPMENT STAGE THERAPEUTIC VACCINES 36
MenB 37
TABLE 13 PRODUCT PROFILE SUMMARY: MENB 37
COMPANY ANALYSIS 38
OVERVIEW 38
GLAXOSMITHKLINE 38
Product and Pipeline Portfolio 38
TABLE 14 PIPELINE SUMMARY: GSK 38
Company Strategy 39
MERCK 40
Product and Pipeline Portfolio 40
TABLE 15 PIPELINE SUMMARY: MERCK 40
Company Strategy 41
NOVARTIS 42
Product and Pipeline Portfolio 42
TABLE 16 PIPELINE SUMMARY: NOVARTIS 42
Product and Pipeline … (Continued) 43
Company Strategy 44
Company Strategy (Continued) 45
PFIZER 46
Product and Pipeline Portfolio 46
TABLE 17 PIPELINE SUMMARY: PFIZER 46
Company Strategy 47
SANOFI-AVENTIS 48
Product and Pipeline Portfolio 49
TABLE 18 PIPELINE SUMMARY: SANOFI-AVENTIS 49
Company Strategy 50
Company Strategy (Continued) 51
Company Strategy (Continued) 52
CHAPTER FOUR: INFECTIOUS DISEASE TREATMENTS 53
INTRODUCTION 53
TABLE 19 GLOBAL MARKET FOR INFECTIOUS DISEASE,
THROUGH 2010 ($ MILLIONS) 54
PRODUCT SUMMARY AND MARKET 54
BACTERIAL DISEASE 54
Overview 54
TABLE 20 CURRENT MARKET BY DRUG CLASS FOR BACTERIAL
DISEASE, THROUGH 2010 ($ MILLIONS) 54
Cephalosporins 55
Penicillins 55
Fluoroquinolones 55
TABLE 21 MARKET FOR LEADING PRODUCTS: BACTERIAL
DISEASE, THROUGH 2010 ($ MILLIONS) 56
VIRAL INFECTIONS 57
TABLE 22 MARKET BY DRUG CLASS FOR VIRAL INFECTION,
THROUGH 2010 ($ MILLIONS) 57
AIDS/HIV 57
Nucleoside Reverse Transcriptase Inhibitor (NRTI) 58
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) 58
Protease Inhibitors 58
TABLE 23 MARKET FOR LEADING PRODUCTS: VIRAL INFECTION
DISEASE, THROUGH 2010 ($ MILLIONS) 59
VACCINES 59
TABLE 24 MARKET BY DRUG CLASS FOR VACCINES, THROUGH
2010 ($ MILLIONS) 59
Hepatitis 60
Hepatitis A and E 60
Hepatitis B 60
Hepatitis C 60
Hepatitis C (Continued) 61
Hepatitis D (with B) 62
Hepatitis G 62
Interferons 62
Antivirals 62
TABLE 25 MARKET FOR LEADING PRODUCTS: VACCINETREATABLE
DISEASE, THROUGH 2010 ($ MILLIONS) 63
FUNGAL INFECTIONS 63
TABLE 26 MARKET BY DRUG CLASS FOR FUNGAL INFECTIONS,
THROUGH 2010 ($ MILLIONS) 63
Fungal Infections (Continued) 64
TABLE 27 MARKET FOR LEADING PRODUCTS: FUNGAL DISEASE,
THROUGH 2010 ($ MILLIONS) 65
TRENDS AND INNOVATIONS IN INFECTIOUS DISEASE 65
KEY TRENDS IN INFECTIOUS DISEASE 65
Large and Growing Opportunity: Drug Resistant
Infections 66
Emerging Markets Open HIV/AIDS Drugs to Fast
Growth 66
Hepatitis C as Major Need Matched with Novel
Last-Stage Compounds 66
Novel Vaccines Drive Future Sales Growth 66
Flu Pandemics Offer Latent Opportunity 67
MARKET FORECAST 67
TABLE 28 MARKET FORECAST FOR INFECTIOUS DISEASE,
THROUGH 2015 ($ MILLIONS) 68
PIPELINE ANALYSIS 68
TABLE 29 PRODUCTS IN DEVELOPMENT BY STAGE AND
INFECTIOUS DISEASE SEGMENT (NUMBER OF
DEVELOPMENTAL PRODUCTS) 69
PROFILES OF KEY PRODUCTS IN DEVELOPMENT 69
RECENTLY APPROVED DRUGS 69
Doribax 69
TABLE 30 PRODUCT PROFILE SUMMARY: DORIBAX 69
Isentress 70
TABLE 31 PRODUCT PROFILE SUMMARY: ISENTRESS 70
Prezista 71
TABLE 32 PRODUCT PROFILE SUMMARY: PREZISTA 71
Prezista (Continued) 72
Selzentry 73
TABLE 33 PRODUCT PROFILE SUMMARY: SELZENTRY 73
Eraxis 74
TABLE 34 PRODUCT PROFILE SUMMARY: ERAXIS 74
Gardasil 75
TABLE 35 PRODUCT PROFILE SUMMARY: GARDASIL 75
Ceftobiprole 76
TABLE 36 PRODUCT PROFILE SUMMARY: CEFTOBIPROLE 76
Cervarix 77
TABLE 37 PRODUCT PROFILE SUMMARY: CERVARIX 77
Cervarix (Continued) 78
Menveo 79
TABLE 38 PRODUCT PROFILE SUMMARY: MENVEO 79
PHASE III DEVELOPMENT STAGE DRUGS 80
Albuferon 80
TABLE 39 PRODUCT PROFILE SUMMARY: ALBUFERON 80
Tygacil 81
TABLE 40 PRODUCT PROFILE SUMMARY: TYGACIL 81
Tygacil (Continued) 82
Numax 83
TABLE 41 PRODUCT PROFILE SUMMARY: NUMAX 83
Telaprevir 84
TABLE 42 PRODUCT PROFILE SUMMARY: TELAPREVIR 84
Vicriviroc 85
TABLE 43 PRODUCT PROFILE SUMMARY: VICRIVIROC 85
Prevnar 13vPnC 86
TABLE 44 PRODUCT PROFILE SUMMARY: PREVNAR 13VPNC 86
COMPANY ANALYSIS 87
ABBOTT 87
Company Overview 87
Products and Services 87
Company Strategy 88
BRISTOL-MYERS SQUIBB 88
Company Overview 88
Products and Services 89
Company Strategy 89
GILEAD SCIENCES 90
Company Overview 90
Products and Services 90
Company Strategy 91
GLAXOSMITHKLINE 91
Company Overview 91
Products and Services 92
Company Strategy 92
JOHNSON & JOHNSON 93
Company Overview 93
Products and Services 93
Company Strategy 94
MERCK 94
Company Overview 95
Products and Services 95
Company Strategy 96
NOVARTIS 96
Company Overview 96
Products and Services 97
Company Strategy 97
PFIZER 98
Company Overview 98
Products and Services 99
Company Strategy 99
SANOFI-AVENTIS 99
Company Overview 99
Products and Services 100
Company Strategy 100
Company Strategy (Continued) 101
CHAPTER FIVE: BIOMARKERS 102
INTRODUCTION 102
TABLE 45 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($
MILLIONS) 103
ENABLING ADVANCEMENTS DRIVING MARKET GROWTH 103
BIOMARKERS DRIVE SPEED, COST AND QUALITY
IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT
SPECTRUM 103
BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT 104
Safety/Toxicology Biomarkers 105
Dose Selection and Dose Optimization 105
Improved Measurement of Therapeutic Efficacy 105
Outcome Biomarkers and Surrogate Endpoints 105
EARLY-STAGE CLINICAL TRIAL APPLICATIONS 106
LATE-STAGE CLINICAL TRIAL APPLICATIONS 107
Phase III 107
Phase IV 107
BIOMARKERS: CHALLENGES AND OPPORTUNITIES 107
SUMMARY 107
CLINICAL VALIDITY: REQUIREMENTS 108
BIOMARKER OPPORTUNITIES 108
PRODUCT SUMMARY AND MARKET 108
GENOMICS 108
TABLE 46 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($
MILLIONS) 109
IMAGING 109
PROTEOMICS 110
BIOINFORMATICS 110
OTHER 111
Metabonomics 111
BIOMARKER ADOPTION BY THE PHARMACEUTICAL
INDUSTRY 111
GROWTH DRIVERS AND RESISTORS 111
FACTORS INFLUENCING BIOMARKER ADOPTION IN
CLINICAL TRIALS 111
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE 112
IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL
TRIALS 112
Merck: Vicriviroc 112
ADDITIONAL CAPABILITIES BY LARGE SERVICE
PLAYERS 113
TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND
PROTEOMICS 113
BIOMARKER MARKET FORECAST 114
TABLE 47 GLOBAL BIOMARKER MARKET FORECAST, THROUGH
2015 ($ MILLIONS) 114
REGULATORY ENVIRONMENT 114
INTRODUCTION 114
ROLE OF THE FOOD AND DRUG ADMINISTRATION 114
TABLE 48 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 115
EUROPEAN MEDICINES AGENCY 116
REGULATORY IMPACT ON DRUG SAFETY 117
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING 117
APPROVED PATENT ANALYSIS 117
TABLE 49 ANNUAL PATENTS FILED AND APPROVED WITH
BIOMARKER CLAIMS IN US, EUROPE, JAPAN, THROUGH 2010 118
COMPETITIVE LANDSCAPE 118
LATE STAGE CLINICAL TRIALS: COMPETITIVE
POSITIONING 118
TABLE 50 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL
STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH
2010 ($ MILLIONS) 119
TABLE 51 GLOBAL MARKET FORECAST FOR CLINICAL STAGE
BIOMARKERS, THROUGH 2015 ($ MILLIONS) 120
APPLICATION BY THERAPY AREA 120
TABLE 52 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER
DELIVERY 120
TABLE 52 (CONTINUED) 121
TABLE 53 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS
BY THERAPEUTIC AREA, THROUGH 2010 ($ MILLIONS) 121
Oncology 121
TABLE 54 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
ONCOLOGY 122
Cardiovascular 122
TABLE 55 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
CARDIOVASCULAR 123
Central Nervous System 123
TABLE 56 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS
DISEASE 124
Immunology 124
TABLE 57 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
IMMUNOLOGY 125
REPRESENTATIVE EXAMPLES WITHIN CANCER AND
IMMUNOLOGY 125
Cancer 125
Elesclomol: Synta 125
Immunology 126
Benlysta: Human Genome Sciences 126
Cancer 126
Hereptin: Roche 126
Expedition and Identity 126
Alzheimer's Trial: Eli Lilly 126
LEADING COMPANIES 127
AFFYMETRIX, INC 127
Company Overview 127
Products and Services 127
Company Strategy 127
BANYAN BIOMARKERS, INC 128
Company Overview 128
Products and Services 128
Company Strategy 128
BG MEDICINE, INC 129
Company Overview 129
Products and Services 129
Company Strategy 129
BIOPHYSICAL CORP 130
Company Overview 130
Products and Services 130
Company Strategy 130
BIOSYSTEMS INTERNATIONAL INC 131
Company Overview 131
Products and Services 131
Company Strategy 131
CAPRION PROTEOMICS INC 132
Company Overview 132
Products and Services 132
Company Strategy 132
CLINICAL DATA, INC 133
Company Overview 133
Products and Services 133
Company Strategy 133
CORRELOGIC SYSTEMS, INC 134
Company Overview 134
Products and Services 134
Company Strategy 134
EPIGENOMICS AG 135
Company Overview 135
Products and Services 135
Company Strategy 135
GENEDATA AG 136
Company Overview 136
Products and Services 136
Company Strategy 137
GENEGO, INC 137
Company Overview 137
Products and Services 137
Company Strategy 137
GENENEWS LTD 138
Company Overview 138
Products and Services 138
Company Strategy 139
CHAPTER SIX: NEXT-GENERATION CARDIOVASCULAR THERAPIES 140
SUMMARY 140
TABLE 58 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE,
THROUGH 2015 ($ MILLIONS) 141
EMERGING DRUG CLASSES 142
P2Y12 AND FACTOR XA INHIBITORS 142
TABLE 59 CARDIOVASCULAR MARKET FORECAST BY DRUG
CLASS, THROUGH 2015 142
TABLE 59 (CONTINUED) 143
Effient (Prasugrel): a Leading P2Y12 Antagonist 143
TABLE 60 P2Y12 MARKET GROWTH AND SHARE, THROUGH 2010 ($
MILLIONS) 144
TABLE 61 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS) 144
TABLE 62 FACTOR XA CURRENT MARKET GROWTH AND SHARE ($
MILLIONS) 145
TABLE 63 FACTOR XA MARKET FORECAST, THROUGH 2015 ($
MILLIONS) 145
P2Y12 Inhibitors and Antagonists 145
Factor Xa Inhibitors 146
Cholesterol-Ester Transfer Protein (CETP) Inhibitor 146
TABLE 64 CETP INHIBITORS IN ACTIVE DEVELOPMENT 147
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET 147
P2Y12 IS A PROVEN TARGET FOR MULTIPLE
INDICATIONS; APPROVALS ARE EXPECTED 147
PLAVIX METABOLIZER 2C19 TRIGGERS US WARNING 147
VALTURNA FIRST TO RECEIVE US APPROVAL AS
COMBINATION THERAPY FOR HYPERTENSION 148
VALTURNA FIRST TO RECEIVE US APPROVAL AS
COMBINATION THERAPY FOR HYPERTENTION 149
ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS,
IN PARTICULAR FACTOR XA 150
APOB-100 AS A NOVEL TREATMENT FOR
HYPERLIPIDEMIA 151
INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH
HDL CHOLESTEROL LEVELS 151
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 152
TABLE 65 MARKET VALUE OF RECENTLY APPROVED DRUGS,
2009-2015 ($ MILLIONS) 153
TABLE 66 SUMMARY PIPELINE FORECAST, 2009-2015 ($ MILLIONS) 153
INDUSTRY STRUCTURE 153
TABLE 67 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH
AND SHARE, THROUGH 2010 ($ MILLIONS) 154
MARKET TRENDS 155
TABLE 68 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS,
THROUGH 2015 ($ MILLIONS) 156
Massive Patent Expiration is a Growth Opportunity for
Generics 156
Market Expansion via Disease Prevention is the Future of
Cardio Care 157
Atrial Fibrillation is a Large and Emerging Disease State 157
Atrial Fibrillation … (Continued) 158
Combination Therapies are Synergistic Revenue
Generators 159
PIPELINE ANALYSIS 160
TABLE 69 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($
MILLIONS) 160
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 160
2010 APPROVALS IN CARDIOVASCULAR THERAPY 161
MULTAQ (DRONEDARONE): SANOFI-AVENTIS 161
TABLE 70 MULTAQ SNAPSHOT 161
XARELTO (RIVAROXABAN): BAYER SCHERING/J&J 162
TABLE 71 XARELTO SNAPSHOT 163
EFFIENT/EFIENT (PRASUGREL): ELI LILLY/DAIICHI
SANKYO 164
TABLE 72 EFFIENT SNAPSHOT 164
RENDIX (DABIGATRAN): BOEHRINGER INGELHEIM 165
TABLE 73 RENDIX SNAPSHOT 166
RECENTLY FILED/PRE-REGISTRATION COMPOUNDS 167
APIXABAN: BRISTOL-MYERS SQUIBB (BMS)/PFIZER 167
TABLE 74 APIXABAN SNAPSHOT 167
BRILINTA (TICAGRELOR/AZD6140): ASTRAZENECA 168
TABLE 75 BRILINTA SNAPSHOT 169
CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID):
ASTRAZENECA/ABBOTT 170
TABLE 76 CERTRIAD SNAPSHOT 170
PHASE II/III COMPOUNDS 171
LCZ696: NOVARTIS 171
TABLE 77 LCZ696 SNAPSHOT 171
EDOXABAN (DU-176B): DAIICHI SANKYO 172
TABLE 78 EDOXABAN (DU-176B) SNAPSHOT 172
SCH 530348 – MERCK 173
TABLE 79 SCH530348 SNAPSHOT 173
TYRISA/DARAPLADIB: GSK 174
TABLE 80 TYRISA SNAPSHOT 174
BETRIXABAN: PORTOLA/MERCK 175
TABLE 81 BETRIXABAN SNAPSHOT 176
PIPELINE ANALYSIS BY COMPANY 177
TABLE 82 PFIZER'S CARDIOVASCULAR PIPELINE 177
TABLE 83 SANOFI-AVENTIS' CARDIOVASCULAR PIPELINE 177
TABLE 84 NOVARTIS' CARDIOVASCULAR PIPELINE 177
TABLE 85 MERCK'S CARDIOVASCULAR PIPELINE 178
TABLE 86 BMS' CARDIOVASCULAR PIPELINE 178
TABLE 87 ASTRA-ZENECA'S CARDIOVASCULAR PIPELINE 178
COMPANY PROFILES 179
SUMMARY 179
TABLE 88 COMPANY REVENUE AND MARKET SHARE ANALYSIS,
THROUGH 2010 ($ MILLIONS) 179
TABLE 89 MARKET FORECAST BY COMPANY, THROUGH 2015 ($
MILLIONS) 180
ASTRAZENECA 181
Business Overview 181
Leading Products 181
Crestor 181
Atacand 182
Certriad 182
Corporate Strategy 182
BRISTOL-MYERS SQUIBB COMPANY 183
Business Overview 183
Leading Products 183
Plavix 183
Apixaban 183
Corporate Strategy 183
MERCK & CO, INC 184
Business Overview 184
Leading Products 184
Vytorin 184
Zetia 185
Cozaar 185
Hyzaar 186
Zocor 186
Corporate Strategy 186
PFIZER, INC 187
Business Overview 187
Leading Products 187
Lipitor 187
Norvasc 188
Revatio 188
Corporate Strategy 188
SANOFI AVENTIS 189
Business Overview 189
Leading Products 189
Plavix 189
Lovenox 190
Multaq 190
Corporate Strategy 191
CHAPTER SEVEN: LEADING OPHTHALMIC TREATMENTS 192
TABLE 90 GLOBAL OPHTHALMIC MARKET FORECAST BY
DISEASE, THROUGH 2015 ($ MILLIONS) 192
LEADING OPHTHALMIC TREATMENTS (CONTINUED) 193
OVERVIEW 194
ESTABLISHED DRUG CLASSES IN OPHTHALMOLOGY 194
EMERGING DRUG CLASSES 194
VEGF-Trap Eye 194
Combination Therapies 194
COMPETITION BETWEEN VEGF INHIBITORS IN WET AMD 195
TABLE 91 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN:
PREVIOUS AND EXPECTED 195
TABLE 91 (CONTINUED) 196
Expected Outcome of CATT Trial: Avastin v Lucentis 196
PIPELINE ANALYSIS 197
TABLE 92 APPROVED PRODUCT SALES FORECAST, 2008-2014 ($
MILLIONS) 197
TABLE 93 PIPELINE SALES FORECAST, 2008-2014 ($ MILLIONS) 198
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 198
STRINGENT REGULATORY PATHWAY EXISTS FOR DRYEYE
DISEASE 198
SUSTAINED DELIVERY IS A COMMON TRAIT AMONG
LEADING PRODUCTS IN DEVELOPMENT 199
SIRNA THERAPIES IN DEVELOPMENT EXPERIENCE
SYSTEMIC SAFETY CONCERNS 200
INDUSTRY STRUCTURE 201
MARKET CONCENTRATION AND PRICE SENSITIVITY 202
TABLE 94 COMPANY BY DISEASE CLASS, 2009 REVENUE ($
MILLIONS) 203
COMPETITIVE FACTORS 203
TABLE 95 LARGE-REVENUE BRANDED DRUG SALES COMING
OFF-PATENT, 2009 204
MARKET TRENDS 204
Demographics Offer Tremendous Long-run Opportunity 204
TABLE 96 REVENUE GROWTH OF OPHTHALMOLOGY AS
COMPARED TO TOTAL PHARMACEUTICAL MARKET, 2005-2010
(% YEAR-OVER-YEAR REVENUE GROWTH) 205
An Increasingly Challenging Global Reimbursement
Environment 205
Sustained Drug Delivery is the Future of Retinal Care 205
Payment Structures Important to Revenue Uptake and
Peak Sales 206
Fundamental Patient Need: Blindness or Impaired Vision
among the Most Debilitating Diseases 206
Combination Therapies Promise Improved Therapeutic
Response 207
Expansion of Prescription Therapies to Rural
Communities 207
TABLE 97 NUMBER OF US HOSPITALS PROVIDING OPHTHALMIC
CARE (NUMBER/%) 208
TABLE 98 NUMBER OF TRAINED, LICENSED, AND CERTIFIED
OPHTHALMOLOGISTS 208
TABLE 99 REVENUE AND SHARE BY LEADING OPHTHALMIC
PLAYERS, 2009 ($ MILLIONS/%) 208
TABLE 100 MARKET ANALYSIS BY DISEASE, 2008 AND 2009 ($
MILLIONS/%) 209
TABLE 101 LEADING OPHTHALMIC THERAPIES, TOTAL SEGMENT,
2009 ($ MILLIONS/%) 209
NOTABLE MERGERS, ACQUISITIONS AND
TRANSACTIONS 210
Roche/Genentech 210
Alcon/Novartis 210
Transaction Summary 210
Proposed Terms of Purchase 210
Proposed Terms … (Continued) 211
Integration Challenges and Opportunities 212
Fovea/Sanofi-Aventis 212
DETAILED PIPELINE REVIEW 213
2009 APPROVALS IN OPHTHALMOLOGY THERAPY 213
Acuvail 213
TABLE 102 SNAPSHOT OF ACUVAIL 213
Clinical Results 213
Bepreve 214
TABLE 103 SNAPSHOT OF BEPREVE 214
Clinical Results 214
Besivance 215
TABLE 104 SNAPSHOT OF BESIVANCE 215
Ozurdex 216
TABLE 105 SNAPSHOT OF OZURDEX 216
Ozurdex (Continued) 217
Zirgan 218
OPHTHALMIC DRUGS IN ADVANCED DEVELOPMENT 218
PHASE III 218
VEGF Trap-Eye 218
TABLE 106 SNAPSHOT OF VEGF TRAP-EYE 219
Clinical Results 219
Iluvien 220
TABLE 107 SNAPSHOT OF ILUVIEN 220
Clinical Results 220
Luveniq 221
TABLE 108 SNAPSHOT OF LUVENIQ 221
PHASE II 222
Ecabet 222
TABLE 109 SNAPSHOT OF ECABET 222
Clinical Results 222
Androgen Tears 223
TABLE 110 SNAPSHOT OF ANDROGEN TEARS 223
PIPELINE ANALYSIS BY COMPANY 224
TABLE 111 ALCON'S OPHTHALMIC PIPELINE 224
TABLE 112 ALLERGAN'S OPHTHALMIC PIPELINE 224
TABLE 113 PFIZER'S OPHTHALMIC PIPELINE 225
TABLE 114 NOVARTIS' OPHTHALMIC PIPELINE 225
TABLE 115 MERCK OPHTHALMIC PIPELINE 225
TABLE 116 SANTEN OPHTHALMIC PIPELINE 225
COMPANY PROFILES 226
SUMMARY 226
ALCON 227
Business Overview 227
Leading Products 227
Pataday 227
Vigamox 227
Nevanac 228
Triesence 228
Tobradex 228
Travatan and Travatan Z 228
Azopt 228
Azarga 228
Duotrav 229
Corporate Strategy 229
ALLERGAN, INC 229
Business Overview 229
Leading Products 229
Restasis and Others 229
Lumigan and Others 230
Corporate Strategy 230
GENENTECH/ROCHE 231
Business Overview 231
Leading Products 231
Lucentis 231
Avastin (Bevacizumab) 232
Corporate Strategy 232
INSPIRE PHARMACEUTICALS, INC 232
Business Overview 233
Leading Products 233
Prolacria (Diquafosol Tetrasodium) 233
Additional Products 233
Corporate Strategy 234
MERCK 234
Business Overview 234
Leading Products 234
Intraocular Pressure Therapies 234
Corporate Strategy 235
NOVARTIS 235
Business Overview 235
Leading Products 235
Lucentis 235
Visudyne 235
Company Strategy 236
OPKO HEALTH 236
Business Overview 236
Leading Products 236
Bevasiranib 236
Civamide 237
Doxovir 237
Company Strategy 237
PFIZER 238
Business Overview 238
Leading Products 238
Xalatan (Latanoprost Ophthalmic Solution) 238
Corporate Strategy 238
POTENTIA PHARMACEUTICALS 239
Business Overview 239
Leading Products 239
POT-4 239
Corporate Strategy 239
QLT INC 240
Business Overview 240
Leading Products 240
Visudyne 240
Corporate Strategy 240
REGENERON 241
Business Overview 241
Leading Products 241
VEGF-Trap Eye 241
Corporate Strategy 241
SANOFI-AVENTIS 242
Business Overview 242
Leading Products 242
Prednisporin 242
FOV2302 242
Corporate Strategy 243
SANTEN SEIYAKU 243
Business Overview 243
Leading Products 244
Hyalein 244
Cravit/Oftaquix 244
Corporate Strategy 244
CHAPTER EIGHT: CNS: NEXT-GENERATION MECHANISMS OF
ACTION 245
TABLE 117 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY
DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 245
CNS: NEXT-GENERATION MECHANISMS …CONTINUED) 246
KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM
MARKET 247
2009 FDA PEDIATRIC ADVISORY COMMITTEE ON
PRESCRIPTION OF ANTIPSYCHOTICS 247
GROWTH SEEN VIA PURSUIT OF ADDITIONAL
INDICATIONS VERSUS NCE APPROVALS 247
ALZHEIMER'S DRUGS IN JAPAN OPEN UP LARGE
OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS 248
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 248
TABLE 118 RECENTLY APPROVED AND PIPELINE FORECAST,
2009-2015 ($ MILLIONS) 248
MARKET TRENDS 249
OVERALL MARKET FLAT: HIGHER MIX OF GENERICS
OFFSET BY HIGHER VOLUME 249
SIGNIFICANT IMPACT OF PATIENT ADVOCACY GROUPS
IN CNS DISEASE 249
GROWTH SEEN VIA PURSUIT OF ADDITIONAL
INDICATIONS VERSUS NCE APPROVALS 249
IMPROVING PERFORMANCE IN DEPRESSION
TREATMENTS 250
ALZHEIMER'S THERAPY CONTINUES TO RECEIVE LARGE
AND IMPORTANT INVESTMENT 250
TABLE 119 PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM
DRUGS, 2010 AND 2015 ($ MILLIONS) 251
TABLE 120 MARKET SHARE BY LEADING CENTRAL NERVOUS
SYSTEM PLAYERS, 2010 ($ MILLIONS/%) 251
TABLE 120 (CONTINUED) 252
TABLE 121 LARGEST REVENUE GENERATING THERAPIES IN THE
CENTRAL NERVOUS SYSTEM DISEASE, THROUGH 2010 ($
MILLIONS) 252
CHAPTER NINE: MARKETS BY DISEASE 253
SUMMARY OF MARKET DYNAMICS 253
TABLE 122 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY
DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 254
PSYCHIATRY 254
MARKET DYNAMICS 254
Market Dynamics (Continued) 255
TABLE 123 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 ($
MILLIONS) 255
TABLE 123 (CONTINUED) 256
DEPRESSION 256
Market Dynamics 256
TABLE 124 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($
MILLIONS) 257
Generic Drug Trends: Depression 257
TABLE 125 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($
MILLIONS) 257
TABLE 125 (CONTINUED) 258
MULTIPLE SCLEROSIS AND PARKINSON'S 258
MARKET DYNAMICS 258
TABLE 126 GLOBAL MS AND PARKINSON'S MARKET THROUGH
2010 ($ MILLIONS) 259
GENERIC DRUG TRENDS: PARKINSON'S 259
TABLE 127 GLOBAL MS AND PARKINSON'S MARKET, THROUGH
2015 ($ MILLIONS) 260
EPILEPSY/CONVULSIONS 260
MARKET DYNAMICS 260
TABLE 128 GLOBAL EPILEPSY MARKET, THROUGH 2010 ($
MILLIONS) 261
TABLE 129 GLOBAL EPILEPSY MARKET, THROUGH 2015 ($
MILLIONS) 261
GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS 262
ALZHEIMER'S 262
MARKET DYNAMICS 262
TABLE 130 GLOBAL ALZHEIMER'S MARKET, THROUGH 2010 ($
MILLIONS) 263
TABLE 131 GLOBAL ALZHEIMER'S MARKET, THROUGH 2015 ($
MILLIONS) 263
TABLE 131 (CONTINUED) 264
GENERIC DRUG TRENDS: ALZHEIMER'S 264
ADHD AND NARCOLEPSY 264
MARKET DYNAMICS 264
TABLE 132 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2010
($ MILLIONS) 265
TABLE 133 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015
($ MILLIONS) 265
GENERIC DRUG TRENDS: ADHD/NARCOLEPSY 266
MIGRAINE AND OTHER CNS DISEASE 266
MARKET DYNAMICS 266
TABLE 134 GLOBAL MIGRAINE MARKET, THROUGH 2015 ($
MILLIONS) 266
TABLE 135 GLOBAL OTHER CENTRAL NERVOUS SYSTEM
MARKET, THROUGH 2015 ($ MILLIONS) 267
PIPELINE ANALYSIS 267
TABLE 136 APPROVED PRODUCT FORECAST, 2009-2015 ($
MILLIONS) 268
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 268
KEY TRENDS IN RESEARCH AND DEVELOPMENT 268
SNRIs Improve the Baseline Performance of Leading
Depression Therapies 268
New Products Provide Larger Opportunities Compared to
Product Extensions 269
Combination Products Yield Greater Therapeutic
Response 269
Alzheimer's Therapy Continues to Receive Large and
Important Investment 269
KEY PRODUCTS UNDER MAJOR CNS DISORDERS 270
Schizophrenia 270
Depression 270
Alzheimer's 271
Parkinson's Disease 272
Epilepsy 272
Insomnia 272
Attention Deficit Hyperactivity Disorder 272
Other Indications 273
2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY 273
PHASE III AND PENDING APPROVAL COMPOUNDS 273
TABLE 137 BAPINEUZUMAB (AAB–001): ELAN/WYETH/PFIZER 273
Phase III and Pending … (Continued) 274
TABLE 138 TELCAGEPANT (MK–0974): MERCK 275
Phase III and Pending … (Continued) 276
TABLE 139 SOLANEZUMAB (LY2062430): ELI LILLY 277
TABLE 140 SEMAGACESTAT (LY450139): ELI LILLY 278
TABLE 141 VILAZODONE: CLINICAL DATA 279
RECENTLY APPROVED/MARKETED DRUGS 280
TABLE 142 STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE):
DAINIPPON SUMITOMO (FORMERLY SEPRACOR) 280
TABLE 143 INTUNIV (GUANFACINE): SHIRE 281
TABLE 144 TREXIMET (SUMATRIPTAN AND NAPROXEN):
GSK/POZEN 282
TABLE 145 PRISTIQ (DESVENLAFAXINE): PFIZER/WYETH 283
Recently Approved/… (Continued) 284
TABLE 146 VIMPAT (LACOSAMIDE): UCB/SCHWARZ PHARMA 285
TABLE 147 DEVELOPMENTAL PRODUCT FORECAST 2009-2015 ($
MILLIONS) 286
CHAPTER TEN: COMPANY PROFILES 287
SUMMARY 287
COMPANIES 287
ABBOTT LABORATORIES 287
Business Overview 287
Therapeutic Areas 288
TABLE 148 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 288
Corporate Strategy 288
ALLERGAN, INC 288
Business Overview 288
Therapeutic Areas 289
TABLE 149 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 289
Corporate Strategy 289
ASTELLAS PHARMA, INC 289
Business Overview 289
Therapeutic Areas 289
TABLE 150 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 290
Corporate Strategy 290
ASTRAZENECA 290
Business Overview 290
Therapeutic Areas 291
TABLE 151 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 291
Corporate Strategy 291
BAYER AG 292
Business Overview 292
Therapeutic Areas 292
TABLE 152 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 293
Corporate Strategy 293
BIOGEN IDEC (FUMAPHARM AG) 293
Business Overview 293
Therapeutic Areas 293
TABLE 153 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 294
Corporate Strategy 294
ELI LILLY & CO 294
Business Overview 294
Therapeutic Areas 294
TABLE 154 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 295
Corporate Strategy 295
FOREST LABORATORIES, INC 295
Business Overview 296
Therapeutic Areas 296
TABLE 155 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 296
Corporate Strategy 296
GLAXOSMITHKLINE (GSK) 297
Business Overview 297
Therapeutic Areas 297
TABLE 156 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 297
Corporate Strategy 297
JOHNSON & JOHNSON 298
Business Overview 298
Therapeutic Areas 298
TABLE 157 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 298
Corporate Strategy 299
MERCK & CO, INC 299
Business Overview 299
Therapeutic Areas 300
TABLE 158 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 300
Corporate Strategy 300
NOVARTIS AG (NOVARTIS PHARMACEUTICALS) 300
Business Overview 300
Therapeutic Areas 301
TABLE 159 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 301
Corporate Strategy 301
PFIZER, INC 301
Business Overview 302
Therapeutic Areas 302
TABLE 160 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 302
Corporate Strategy 302
SANOFI-AVENTIS 303
Business Overview 303
Therapeutic Areas 303
TABLE 161 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 304
Corporate Strategy 304
SHIRE PHARMACEUTICALS GROUP, PLC 304
Business Overview 304
Therapeutic Areas 304
TABLE 162 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 305
Corporate Strategy 305
Business Overview 305
Therapeutic Areas 306
TABLE 163 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 306
Corporate Strategy 306
TEVA PHARMACEUTICAL INDUSTRIES LTD 306
Business Overview 306
Therapeutic Areas 307
TABLE 164 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 307
Corporate Strategy 307
WATSON PHARMACEUTICALS, INC 307
Business Overview 308
Therapeutic Areas 308
TABLE 165 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 308
Corporate Strategy 308
CHAPTER ELEVEN: CANCER TRENDS: EVOLVING THERAPIES 309
INTRODUCTION 309
TRENDS IN ONCOLOGY DRUG DEVELOPMENT 309
PERSONLIZED TREATMENTS BECOMING STANDARD OF
CARE 309
VACCINES IMPROVE ACCESS TO IMMUNE RESPONSE 310
COST TO SERVE IS NEXT FRONTIER OF
DIFFERENTIATION 310
ONCOLOGISTS REPLACE DRUG COMPANIES TO DELIVER
COMBINATION THERAPY 311
TABLE 166 ONCOLOGY MARKETS BY TYPE OF THERAPY,
THROUGH 2010 ($ MILLIONS) 311
MARKET ANALYSIS BY DRUG CLASS 311
KEY RECENT EVENTS IN THE CANCER MARKET 312
FDA WITHDRAWS BREAST CANCER INDICATION FOR
AVASTIN 312
MYLOTARG WITHDRAWN BASED ON BOTH SAFETY AND
EFFICACY CONCERNS 312
JEVTANA APPROVED FOR METASTATIC HORMONEREFRACTORY
PROSTATE CANCER 313
STIMUVAX PHASE III TRIALS RESUMED BY MERCK
SERONO 313
FDA CONTINUES GARDASIL REVIEW 314
NEOPLASIA THERAPY 314
COMPETITIVE DYNAMICS OF NEOPLASIA THERAPY 314
TABLE 167 ONCOLOGY MARKETS BY DRUG CLASS, THROUGH 2010
($ MILLIONS) 315
LEADING NEOPLASIA THERAPY BRANDS 316
TOTAL NEOPLASIA THERAPY MARKET 316
TABLE 168 2010 ONCOLOGY MARKETS BY LARGEST
THERAPEUTIC DRUGS, THROUGH 2010 ($ MILLIONS) 316
NEOPLASIA THERAPY MAB MARKET ANALYSIS 317
MARKET DYNAMICS 317
PRODUCT REVIEW 317
Erbitux (Cetuximab) 317
Nexavar (Sorafenib) 318
NEOPLASIA THERAPY PROTEIN KINASE INHIBITORS 319
MARKET DYNAMICS
To order this report:
Drug and Medication Industry: Markets for Emerging Pharmaceutical Technologies
Drug and Medication Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Markets for Emerging Pharmaceutical Technologies
http://www.reportlinker.com/p0492944/Markets-for-Emerging-Pharmaceutical-Technologies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Advertisement
REPORT HIGHLIGHTS
*
As a segment, therapeutic vaccines recorded $19.3 billion in 2010, a figure that is expected to grow to $31.9 billion by 2015, demonstrating a compound annual growth rate (CAGR) of 10.6%.
*
Treatment for infectious disease continues to advance, growing from a 2010 figure of $86.5 billion to $116 billion by 2015, a compound annual growth rate (CAGR) of 6.1%. Large and important areas including Hepatitis and HIV/AIDS will drive this increase.
*
Biomarkers, as an enabling element within drug development, will experience explosive growth, increasing from a current $13.5 billion to $33.3 billion in 2015, a 19.8% compound annual growth rate (CAGR) for the forecast period. The increased application of biomarkers in nonclinical, clinical and point of care areas in addition to stratifying patient populations to increase targeted applications of medicine will drive the increase.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of emerging pharmaceutical technologies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the emerging technologies segment. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.
The emerging technologies therapeutic market presents the largest of all opportunities in representative disease subsegments. Market growth has been spurred by the introduction of differentiated therapies due to novel mechanisms of action, such as P2Y12 inhibitors and factor Xa inhibitors.
This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets, by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the FDA, and those products expected to be approved within the forecast period are projected. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For all areas, including the very large markets segments such as infectious disease and cardiovascular, specific mechanisms of action are discussed in detail.
The report includes analysis of leading and emerging competitors in the current worldwide emerging technologies market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.
Market figures are based on revenues at the manufacturers' level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.
Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the Emerging Technologies market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease subsegment.
Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician's prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented are on a global basis, unless specifically noted.
INTENDED AUDIENCE
This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the Emerging Technologies market, its products, its industry participants and its future.
The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:
* Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D
* Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study
* Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis
* Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.
The overall emerging technologies sector is comprised of a variety of fast growing and independent segments. For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment. Within each subsection, there is a detailed forecast for each driving mechanism, or relevant area of growth.
Information to prepare this report was obtained from participating and emerging companies in the emerging technologies area; American Heart Association; the National Heart, Lung, and Blood Institute; articles published in medical journals such as American Heart Journal, Circulation, Journal of Emerging Technologies Pharmacology, Lancet, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks; and others. Population estimates are based on those reported by the international data base of the U.S. Census Bureau.
Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.
CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY AND INFORMATION SOURCES 3
RELATED REPORTS 4
BCC ONLINE SERVICES 4
DISCLAIMER 5
CHAPTER TWO: SUMMARY 6
SUMMARY TABLE GLOBAL EMERGING TECHNOLOGIES
FORECAST BY AREA, THROUGH 2015 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL EMERGING TECHNOLOGIES
FORECAST BY AREA, 2009-2015 ($ MILLIONS) 7
SUMMARY (CONTINUED) 8
CHAPTER THREE: THERAPEUTIC VACCINES 9
OVERVIEW 9
TABLE 1 GLOBAL MARKET FOR THERAPEUTIC VACCINES,
THROUGH 2010 ($ MILLIONS) 9
KEY EVENTS IN THE THERAPEUTIC VACCINE MARKET 10
EXPANDING SEGMENT: PROPHYLACTIC CANCER
VACCINES 10
VACCINE OPPORTUNITY SLACKENING DUE TO
OVERCAPACITY 10
CELL CULTURE AND ADJUVANT TECHNOLOGY
ENABLE THERAPEUTIC VACCINES 11
TABLE 2 MARKET FORECAST FOR THERAPEUTIC VACCINES,
THROUGH 2015 ($ MILLIONS) 11
LEADING VACCINE BRANDS 12
TABLE 3 LEADING VACCINE BRANDS, THROUGH 2010 ($
MILLIONS) 12
HEPATITIS VACCINES 12
PRODUCTS SUMMARY 12
TABLE 4 MARKET FOR LEADING VACCINES: HEPATITIS
SEGMENT, THROUGH 2010 ($ MILLIONS) 13
MARKET DYNAMICS 13
INFLUENZA VACCINES 14
TABLE 5 MARKET FOR LEADING VACCINES: INFLUENZA
SEGMENT, THROUGH 2010 ($ MILLIONS) 14
H1N1 SWINE FLU 15
MARKET DYNAMICS 15
PNEUMONIA VACCINES 16
MARKET DYNAMICS 16
MENINGITIS VACCINES 17
TABLE 6 MARKET FOR LEADING VACCINES: MENINGITIS
SEGMENT, THROUGH 2010 ($ MILLIONS) 17
MARKET DYNAMICS 18
OTHER VACCINES 18
HUMAN PAPILLOMAVIRUS (HPV) VACCINES 18
MARKET DYNAMICS 18
Market Dynamics (Continued) 19
EMERGING TARGETS IN THERAPEUTIC VACCINES 20
THE NEW VACCINE STRATEGY: THERAPEUTIC
VACCINES 20
Therapeutic Vaccines with Traditional Strategies 20
Antigen/Whole Cell Vaccines 20
Therapeutic Vaccines with Novel and Advanced
Strategies 20
Dendritic Cell Vaccines 20
Cytolytic Viral Vaccines 21
DNA Vaccines 21
AFFiTOPE/AFFiTOME 22
Beta Amyloid 22
Somatostatin GHRH 23
Plasmid Encorders 24
Telomerase Endogenous Reverse Transcriptase (TERT) 25
PIPELINE ANALYSIS 26
INTRODUCTION 26
RECENTLY APPROVED PRODUCTS 26
Menveo 26
TABLE 7 PRODUCT PROFILE SUMMARY: MENVEO 26
Menveo (Continued) 27
Prevnar 13vPnC 28
TABLE 8 PRODUCT PROFILE SUMMARY: PREVNAR 13VPNC 28
Prevnar 13vPnC (Continued) 29
Cervarix 30
TABLE 9 PRODUCT PROFILE SUMMARY: CERVARIX 30
Synflorix 31
TABLE 10 PRODUCT PROFILE SUMMARY: SYNFLORIX 31
Synflorix (Continued) 32
Ixiaro/Jespect 33
TABLE 11 PRODUCT PROFILE SUMMARY: IXIARO/JESPECT 33
Provenge 34
TABLE 12 PRODUCT PROFILE SUMMARY: PROVENGE 34
Provenge (Continued) 35
Provenge (Continued) 36
DEVELOPMENT STAGE THERAPEUTIC VACCINES 36
MenB 37
TABLE 13 PRODUCT PROFILE SUMMARY: MENB 37
COMPANY ANALYSIS 38
OVERVIEW 38
GLAXOSMITHKLINE 38
Product and Pipeline Portfolio 38
TABLE 14 PIPELINE SUMMARY: GSK 38
Company Strategy 39
MERCK 40
Product and Pipeline Portfolio 40
TABLE 15 PIPELINE SUMMARY: MERCK 40
Company Strategy 41
NOVARTIS 42
Product and Pipeline Portfolio 42
TABLE 16 PIPELINE SUMMARY: NOVARTIS 42
Product and Pipeline … (Continued) 43
Company Strategy 44
Company Strategy (Continued) 45
PFIZER 46
Product and Pipeline Portfolio 46
TABLE 17 PIPELINE SUMMARY: PFIZER 46
Company Strategy 47
SANOFI-AVENTIS 48
Product and Pipeline Portfolio 49
TABLE 18 PIPELINE SUMMARY: SANOFI-AVENTIS 49
Company Strategy 50
Company Strategy (Continued) 51
Company Strategy (Continued) 52
CHAPTER FOUR: INFECTIOUS DISEASE TREATMENTS 53
INTRODUCTION 53
TABLE 19 GLOBAL MARKET FOR INFECTIOUS DISEASE,
THROUGH 2010 ($ MILLIONS) 54
PRODUCT SUMMARY AND MARKET 54
BACTERIAL DISEASE 54
Overview 54
TABLE 20 CURRENT MARKET BY DRUG CLASS FOR BACTERIAL
DISEASE, THROUGH 2010 ($ MILLIONS) 54
Cephalosporins 55
Penicillins 55
Fluoroquinolones 55
TABLE 21 MARKET FOR LEADING PRODUCTS: BACTERIAL
DISEASE, THROUGH 2010 ($ MILLIONS) 56
VIRAL INFECTIONS 57
TABLE 22 MARKET BY DRUG CLASS FOR VIRAL INFECTION,
THROUGH 2010 ($ MILLIONS) 57
AIDS/HIV 57
Nucleoside Reverse Transcriptase Inhibitor (NRTI) 58
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) 58
Protease Inhibitors 58
TABLE 23 MARKET FOR LEADING PRODUCTS: VIRAL INFECTION
DISEASE, THROUGH 2010 ($ MILLIONS) 59
VACCINES 59
TABLE 24 MARKET BY DRUG CLASS FOR VACCINES, THROUGH
2010 ($ MILLIONS) 59
Hepatitis 60
Hepatitis A and E 60
Hepatitis B 60
Hepatitis C 60
Hepatitis C (Continued) 61
Hepatitis D (with B) 62
Hepatitis G 62
Interferons 62
Antivirals 62
TABLE 25 MARKET FOR LEADING PRODUCTS: VACCINETREATABLE
DISEASE, THROUGH 2010 ($ MILLIONS) 63
FUNGAL INFECTIONS 63
TABLE 26 MARKET BY DRUG CLASS FOR FUNGAL INFECTIONS,
THROUGH 2010 ($ MILLIONS) 63
Fungal Infections (Continued) 64
TABLE 27 MARKET FOR LEADING PRODUCTS: FUNGAL DISEASE,
THROUGH 2010 ($ MILLIONS) 65
TRENDS AND INNOVATIONS IN INFECTIOUS DISEASE 65
KEY TRENDS IN INFECTIOUS DISEASE 65
Large and Growing Opportunity: Drug Resistant
Infections 66
Emerging Markets Open HIV/AIDS Drugs to Fast
Growth 66
Hepatitis C as Major Need Matched with Novel
Last-Stage Compounds 66
Novel Vaccines Drive Future Sales Growth 66
Flu Pandemics Offer Latent Opportunity 67
MARKET FORECAST 67
TABLE 28 MARKET FORECAST FOR INFECTIOUS DISEASE,
THROUGH 2015 ($ MILLIONS) 68
PIPELINE ANALYSIS 68
TABLE 29 PRODUCTS IN DEVELOPMENT BY STAGE AND
INFECTIOUS DISEASE SEGMENT (NUMBER OF
DEVELOPMENTAL PRODUCTS) 69
PROFILES OF KEY PRODUCTS IN DEVELOPMENT 69
RECENTLY APPROVED DRUGS 69
Doribax 69
TABLE 30 PRODUCT PROFILE SUMMARY: DORIBAX 69
Isentress 70
TABLE 31 PRODUCT PROFILE SUMMARY: ISENTRESS 70
Prezista 71
TABLE 32 PRODUCT PROFILE SUMMARY: PREZISTA 71
Prezista (Continued) 72
Selzentry 73
TABLE 33 PRODUCT PROFILE SUMMARY: SELZENTRY 73
Eraxis 74
TABLE 34 PRODUCT PROFILE SUMMARY: ERAXIS 74
Gardasil 75
TABLE 35 PRODUCT PROFILE SUMMARY: GARDASIL 75
Ceftobiprole 76
TABLE 36 PRODUCT PROFILE SUMMARY: CEFTOBIPROLE 76
Cervarix 77
TABLE 37 PRODUCT PROFILE SUMMARY: CERVARIX 77
Cervarix (Continued) 78
Menveo 79
TABLE 38 PRODUCT PROFILE SUMMARY: MENVEO 79
PHASE III DEVELOPMENT STAGE DRUGS 80
Albuferon 80
TABLE 39 PRODUCT PROFILE SUMMARY: ALBUFERON 80
Tygacil 81
TABLE 40 PRODUCT PROFILE SUMMARY: TYGACIL 81
Tygacil (Continued) 82
Numax 83
TABLE 41 PRODUCT PROFILE SUMMARY: NUMAX 83
Telaprevir 84
TABLE 42 PRODUCT PROFILE SUMMARY: TELAPREVIR 84
Vicriviroc 85
TABLE 43 PRODUCT PROFILE SUMMARY: VICRIVIROC 85
Prevnar 13vPnC 86
TABLE 44 PRODUCT PROFILE SUMMARY: PREVNAR 13VPNC 86
COMPANY ANALYSIS 87
ABBOTT 87
Company Overview 87
Products and Services 87
Company Strategy 88
BRISTOL-MYERS SQUIBB 88
Company Overview 88
Products and Services 89
Company Strategy 89
GILEAD SCIENCES 90
Company Overview 90
Products and Services 90
Company Strategy 91
GLAXOSMITHKLINE 91
Company Overview 91
Products and Services 92
Company Strategy 92
JOHNSON & JOHNSON 93
Company Overview 93
Products and Services 93
Company Strategy 94
MERCK 94
Company Overview 95
Products and Services 95
Company Strategy 96
NOVARTIS 96
Company Overview 96
Products and Services 97
Company Strategy 97
PFIZER 98
Company Overview 98
Products and Services 99
Company Strategy 99
SANOFI-AVENTIS 99
Company Overview 99
Products and Services 100
Company Strategy 100
Company Strategy (Continued) 101
CHAPTER FIVE: BIOMARKERS 102
INTRODUCTION 102
TABLE 45 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($
MILLIONS) 103
ENABLING ADVANCEMENTS DRIVING MARKET GROWTH 103
BIOMARKERS DRIVE SPEED, COST AND QUALITY
IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT
SPECTRUM 103
BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT 104
Safety/Toxicology Biomarkers 105
Dose Selection and Dose Optimization 105
Improved Measurement of Therapeutic Efficacy 105
Outcome Biomarkers and Surrogate Endpoints 105
EARLY-STAGE CLINICAL TRIAL APPLICATIONS 106
LATE-STAGE CLINICAL TRIAL APPLICATIONS 107
Phase III 107
Phase IV 107
BIOMARKERS: CHALLENGES AND OPPORTUNITIES 107
SUMMARY 107
CLINICAL VALIDITY: REQUIREMENTS 108
BIOMARKER OPPORTUNITIES 108
PRODUCT SUMMARY AND MARKET 108
GENOMICS 108
TABLE 46 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($
MILLIONS) 109
IMAGING 109
PROTEOMICS 110
BIOINFORMATICS 110
OTHER 111
Metabonomics 111
BIOMARKER ADOPTION BY THE PHARMACEUTICAL
INDUSTRY 111
GROWTH DRIVERS AND RESISTORS 111
FACTORS INFLUENCING BIOMARKER ADOPTION IN
CLINICAL TRIALS 111
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE 112
IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL
TRIALS 112
Merck: Vicriviroc 112
ADDITIONAL CAPABILITIES BY LARGE SERVICE
PLAYERS 113
TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND
PROTEOMICS 113
BIOMARKER MARKET FORECAST 114
TABLE 47 GLOBAL BIOMARKER MARKET FORECAST, THROUGH
2015 ($ MILLIONS) 114
REGULATORY ENVIRONMENT 114
INTRODUCTION 114
ROLE OF THE FOOD AND DRUG ADMINISTRATION 114
TABLE 48 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 115
EUROPEAN MEDICINES AGENCY 116
REGULATORY IMPACT ON DRUG SAFETY 117
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING 117
APPROVED PATENT ANALYSIS 117
TABLE 49 ANNUAL PATENTS FILED AND APPROVED WITH
BIOMARKER CLAIMS IN US, EUROPE, JAPAN, THROUGH 2010 118
COMPETITIVE LANDSCAPE 118
LATE STAGE CLINICAL TRIALS: COMPETITIVE
POSITIONING 118
TABLE 50 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL
STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH
2010 ($ MILLIONS) 119
TABLE 51 GLOBAL MARKET FORECAST FOR CLINICAL STAGE
BIOMARKERS, THROUGH 2015 ($ MILLIONS) 120
APPLICATION BY THERAPY AREA 120
TABLE 52 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER
DELIVERY 120
TABLE 52 (CONTINUED) 121
TABLE 53 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS
BY THERAPEUTIC AREA, THROUGH 2010 ($ MILLIONS) 121
Oncology 121
TABLE 54 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
ONCOLOGY 122
Cardiovascular 122
TABLE 55 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
CARDIOVASCULAR 123
Central Nervous System 123
TABLE 56 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS
DISEASE 124
Immunology 124
TABLE 57 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
IMMUNOLOGY 125
REPRESENTATIVE EXAMPLES WITHIN CANCER AND
IMMUNOLOGY 125
Cancer 125
Elesclomol: Synta 125
Immunology 126
Benlysta: Human Genome Sciences 126
Cancer 126
Hereptin: Roche 126
Expedition and Identity 126
Alzheimer's Trial: Eli Lilly 126
LEADING COMPANIES 127
AFFYMETRIX, INC 127
Company Overview 127
Products and Services 127
Company Strategy 127
BANYAN BIOMARKERS, INC 128
Company Overview 128
Products and Services 128
Company Strategy 128
BG MEDICINE, INC 129
Company Overview 129
Products and Services 129
Company Strategy 129
BIOPHYSICAL CORP 130
Company Overview 130
Products and Services 130
Company Strategy 130
BIOSYSTEMS INTERNATIONAL INC 131
Company Overview 131
Products and Services 131
Company Strategy 131
CAPRION PROTEOMICS INC 132
Company Overview 132
Products and Services 132
Company Strategy 132
CLINICAL DATA, INC 133
Company Overview 133
Products and Services 133
Company Strategy 133
CORRELOGIC SYSTEMS, INC 134
Company Overview 134
Products and Services 134
Company Strategy 134
EPIGENOMICS AG 135
Company Overview 135
Products and Services 135
Company Strategy 135
GENEDATA AG 136
Company Overview 136
Products and Services 136
Company Strategy 137
GENEGO, INC 137
Company Overview 137
Products and Services 137
Company Strategy 137
GENENEWS LTD 138
Company Overview 138
Products and Services 138
Company Strategy 139
CHAPTER SIX: NEXT-GENERATION CARDIOVASCULAR THERAPIES 140
SUMMARY 140
TABLE 58 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE,
THROUGH 2015 ($ MILLIONS) 141
EMERGING DRUG CLASSES 142
P2Y12 AND FACTOR XA INHIBITORS 142
TABLE 59 CARDIOVASCULAR MARKET FORECAST BY DRUG
CLASS, THROUGH 2015 142
TABLE 59 (CONTINUED) 143
Effient (Prasugrel): a Leading P2Y12 Antagonist 143
TABLE 60 P2Y12 MARKET GROWTH AND SHARE, THROUGH 2010 ($
MILLIONS) 144
TABLE 61 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS) 144
TABLE 62 FACTOR XA CURRENT MARKET GROWTH AND SHARE ($
MILLIONS) 145
TABLE 63 FACTOR XA MARKET FORECAST, THROUGH 2015 ($
MILLIONS) 145
P2Y12 Inhibitors and Antagonists 145
Factor Xa Inhibitors 146
Cholesterol-Ester Transfer Protein (CETP) Inhibitor 146
TABLE 64 CETP INHIBITORS IN ACTIVE DEVELOPMENT 147
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET 147
P2Y12 IS A PROVEN TARGET FOR MULTIPLE
INDICATIONS; APPROVALS ARE EXPECTED 147
PLAVIX METABOLIZER 2C19 TRIGGERS US WARNING 147
VALTURNA FIRST TO RECEIVE US APPROVAL AS
COMBINATION THERAPY FOR HYPERTENSION 148
VALTURNA FIRST TO RECEIVE US APPROVAL AS
COMBINATION THERAPY FOR HYPERTENTION 149
ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS,
IN PARTICULAR FACTOR XA 150
APOB-100 AS A NOVEL TREATMENT FOR
HYPERLIPIDEMIA 151
INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH
HDL CHOLESTEROL LEVELS 151
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 152
TABLE 65 MARKET VALUE OF RECENTLY APPROVED DRUGS,
2009-2015 ($ MILLIONS) 153
TABLE 66 SUMMARY PIPELINE FORECAST, 2009-2015 ($ MILLIONS) 153
INDUSTRY STRUCTURE 153
TABLE 67 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH
AND SHARE, THROUGH 2010 ($ MILLIONS) 154
MARKET TRENDS 155
TABLE 68 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS,
THROUGH 2015 ($ MILLIONS) 156
Massive Patent Expiration is a Growth Opportunity for
Generics 156
Market Expansion via Disease Prevention is the Future of
Cardio Care 157
Atrial Fibrillation is a Large and Emerging Disease State 157
Atrial Fibrillation … (Continued) 158
Combination Therapies are Synergistic Revenue
Generators 159
PIPELINE ANALYSIS 160
TABLE 69 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($
MILLIONS) 160
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 160
2010 APPROVALS IN CARDIOVASCULAR THERAPY 161
MULTAQ (DRONEDARONE): SANOFI-AVENTIS 161
TABLE 70 MULTAQ SNAPSHOT 161
XARELTO (RIVAROXABAN): BAYER SCHERING/J&J 162
TABLE 71 XARELTO SNAPSHOT 163
EFFIENT/EFIENT (PRASUGREL): ELI LILLY/DAIICHI
SANKYO 164
TABLE 72 EFFIENT SNAPSHOT 164
RENDIX (DABIGATRAN): BOEHRINGER INGELHEIM 165
TABLE 73 RENDIX SNAPSHOT 166
RECENTLY FILED/PRE-REGISTRATION COMPOUNDS 167
APIXABAN: BRISTOL-MYERS SQUIBB (BMS)/PFIZER 167
TABLE 74 APIXABAN SNAPSHOT 167
BRILINTA (TICAGRELOR/AZD6140): ASTRAZENECA 168
TABLE 75 BRILINTA SNAPSHOT 169
CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID):
ASTRAZENECA/ABBOTT 170
TABLE 76 CERTRIAD SNAPSHOT 170
PHASE II/III COMPOUNDS 171
LCZ696: NOVARTIS 171
TABLE 77 LCZ696 SNAPSHOT 171
EDOXABAN (DU-176B): DAIICHI SANKYO 172
TABLE 78 EDOXABAN (DU-176B) SNAPSHOT 172
SCH 530348 – MERCK 173
TABLE 79 SCH530348 SNAPSHOT 173
TYRISA/DARAPLADIB: GSK 174
TABLE 80 TYRISA SNAPSHOT 174
BETRIXABAN: PORTOLA/MERCK 175
TABLE 81 BETRIXABAN SNAPSHOT 176
PIPELINE ANALYSIS BY COMPANY 177
TABLE 82 PFIZER'S CARDIOVASCULAR PIPELINE 177
TABLE 83 SANOFI-AVENTIS' CARDIOVASCULAR PIPELINE 177
TABLE 84 NOVARTIS' CARDIOVASCULAR PIPELINE 177
TABLE 85 MERCK'S CARDIOVASCULAR PIPELINE 178
TABLE 86 BMS' CARDIOVASCULAR PIPELINE 178
TABLE 87 ASTRA-ZENECA'S CARDIOVASCULAR PIPELINE 178
COMPANY PROFILES 179
SUMMARY 179
TABLE 88 COMPANY REVENUE AND MARKET SHARE ANALYSIS,
THROUGH 2010 ($ MILLIONS) 179
TABLE 89 MARKET FORECAST BY COMPANY, THROUGH 2015 ($
MILLIONS) 180
ASTRAZENECA 181
Business Overview 181
Leading Products 181
Crestor 181
Atacand 182
Certriad 182
Corporate Strategy 182
BRISTOL-MYERS SQUIBB COMPANY 183
Business Overview 183
Leading Products 183
Plavix 183
Apixaban 183
Corporate Strategy 183
MERCK & CO, INC 184
Business Overview 184
Leading Products 184
Vytorin 184
Zetia 185
Cozaar 185
Hyzaar 186
Zocor 186
Corporate Strategy 186
PFIZER, INC 187
Business Overview 187
Leading Products 187
Lipitor 187
Norvasc 188
Revatio 188
Corporate Strategy 188
SANOFI AVENTIS 189
Business Overview 189
Leading Products 189
Plavix 189
Lovenox 190
Multaq 190
Corporate Strategy 191
CHAPTER SEVEN: LEADING OPHTHALMIC TREATMENTS 192
TABLE 90 GLOBAL OPHTHALMIC MARKET FORECAST BY
DISEASE, THROUGH 2015 ($ MILLIONS) 192
LEADING OPHTHALMIC TREATMENTS (CONTINUED) 193
OVERVIEW 194
ESTABLISHED DRUG CLASSES IN OPHTHALMOLOGY 194
EMERGING DRUG CLASSES 194
VEGF-Trap Eye 194
Combination Therapies 194
COMPETITION BETWEEN VEGF INHIBITORS IN WET AMD 195
TABLE 91 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN:
PREVIOUS AND EXPECTED 195
TABLE 91 (CONTINUED) 196
Expected Outcome of CATT Trial: Avastin v Lucentis 196
PIPELINE ANALYSIS 197
TABLE 92 APPROVED PRODUCT SALES FORECAST, 2008-2014 ($
MILLIONS) 197
TABLE 93 PIPELINE SALES FORECAST, 2008-2014 ($ MILLIONS) 198
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 198
STRINGENT REGULATORY PATHWAY EXISTS FOR DRYEYE
DISEASE 198
SUSTAINED DELIVERY IS A COMMON TRAIT AMONG
LEADING PRODUCTS IN DEVELOPMENT 199
SIRNA THERAPIES IN DEVELOPMENT EXPERIENCE
SYSTEMIC SAFETY CONCERNS 200
INDUSTRY STRUCTURE 201
MARKET CONCENTRATION AND PRICE SENSITIVITY 202
TABLE 94 COMPANY BY DISEASE CLASS, 2009 REVENUE ($
MILLIONS) 203
COMPETITIVE FACTORS 203
TABLE 95 LARGE-REVENUE BRANDED DRUG SALES COMING
OFF-PATENT, 2009 204
MARKET TRENDS 204
Demographics Offer Tremendous Long-run Opportunity 204
TABLE 96 REVENUE GROWTH OF OPHTHALMOLOGY AS
COMPARED TO TOTAL PHARMACEUTICAL MARKET, 2005-2010
(% YEAR-OVER-YEAR REVENUE GROWTH) 205
An Increasingly Challenging Global Reimbursement
Environment 205
Sustained Drug Delivery is the Future of Retinal Care 205
Payment Structures Important to Revenue Uptake and
Peak Sales 206
Fundamental Patient Need: Blindness or Impaired Vision
among the Most Debilitating Diseases 206
Combination Therapies Promise Improved Therapeutic
Response 207
Expansion of Prescription Therapies to Rural
Communities 207
TABLE 97 NUMBER OF US HOSPITALS PROVIDING OPHTHALMIC
CARE (NUMBER/%) 208
TABLE 98 NUMBER OF TRAINED, LICENSED, AND CERTIFIED
OPHTHALMOLOGISTS 208
TABLE 99 REVENUE AND SHARE BY LEADING OPHTHALMIC
PLAYERS, 2009 ($ MILLIONS/%) 208
TABLE 100 MARKET ANALYSIS BY DISEASE, 2008 AND 2009 ($
MILLIONS/%) 209
TABLE 101 LEADING OPHTHALMIC THERAPIES, TOTAL SEGMENT,
2009 ($ MILLIONS/%) 209
NOTABLE MERGERS, ACQUISITIONS AND
TRANSACTIONS 210
Roche/Genentech 210
Alcon/Novartis 210
Transaction Summary 210
Proposed Terms of Purchase 210
Proposed Terms … (Continued) 211
Integration Challenges and Opportunities 212
Fovea/Sanofi-Aventis 212
DETAILED PIPELINE REVIEW 213
2009 APPROVALS IN OPHTHALMOLOGY THERAPY 213
Acuvail 213
TABLE 102 SNAPSHOT OF ACUVAIL 213
Clinical Results 213
Bepreve 214
TABLE 103 SNAPSHOT OF BEPREVE 214
Clinical Results 214
Besivance 215
TABLE 104 SNAPSHOT OF BESIVANCE 215
Ozurdex 216
TABLE 105 SNAPSHOT OF OZURDEX 216
Ozurdex (Continued) 217
Zirgan 218
OPHTHALMIC DRUGS IN ADVANCED DEVELOPMENT 218
PHASE III 218
VEGF Trap-Eye 218
TABLE 106 SNAPSHOT OF VEGF TRAP-EYE 219
Clinical Results 219
Iluvien 220
TABLE 107 SNAPSHOT OF ILUVIEN 220
Clinical Results 220
Luveniq 221
TABLE 108 SNAPSHOT OF LUVENIQ 221
PHASE II 222
Ecabet 222
TABLE 109 SNAPSHOT OF ECABET 222
Clinical Results 222
Androgen Tears 223
TABLE 110 SNAPSHOT OF ANDROGEN TEARS 223
PIPELINE ANALYSIS BY COMPANY 224
TABLE 111 ALCON'S OPHTHALMIC PIPELINE 224
TABLE 112 ALLERGAN'S OPHTHALMIC PIPELINE 224
TABLE 113 PFIZER'S OPHTHALMIC PIPELINE 225
TABLE 114 NOVARTIS' OPHTHALMIC PIPELINE 225
TABLE 115 MERCK OPHTHALMIC PIPELINE 225
TABLE 116 SANTEN OPHTHALMIC PIPELINE 225
COMPANY PROFILES 226
SUMMARY 226
ALCON 227
Business Overview 227
Leading Products 227
Pataday 227
Vigamox 227
Nevanac 228
Triesence 228
Tobradex 228
Travatan and Travatan Z 228
Azopt 228
Azarga 228
Duotrav 229
Corporate Strategy 229
ALLERGAN, INC 229
Business Overview 229
Leading Products 229
Restasis and Others 229
Lumigan and Others 230
Corporate Strategy 230
GENENTECH/ROCHE 231
Business Overview 231
Leading Products 231
Lucentis 231
Avastin (Bevacizumab) 232
Corporate Strategy 232
INSPIRE PHARMACEUTICALS, INC 232
Business Overview 233
Leading Products 233
Prolacria (Diquafosol Tetrasodium) 233
Additional Products 233
Corporate Strategy 234
MERCK 234
Business Overview 234
Leading Products 234
Intraocular Pressure Therapies 234
Corporate Strategy 235
NOVARTIS 235
Business Overview 235
Leading Products 235
Lucentis 235
Visudyne 235
Company Strategy 236
OPKO HEALTH 236
Business Overview 236
Leading Products 236
Bevasiranib 236
Civamide 237
Doxovir 237
Company Strategy 237
PFIZER 238
Business Overview 238
Leading Products 238
Xalatan (Latanoprost Ophthalmic Solution) 238
Corporate Strategy 238
POTENTIA PHARMACEUTICALS 239
Business Overview 239
Leading Products 239
POT-4 239
Corporate Strategy 239
QLT INC 240
Business Overview 240
Leading Products 240
Visudyne 240
Corporate Strategy 240
REGENERON 241
Business Overview 241
Leading Products 241
VEGF-Trap Eye 241
Corporate Strategy 241
SANOFI-AVENTIS 242
Business Overview 242
Leading Products 242
Prednisporin 242
FOV2302 242
Corporate Strategy 243
SANTEN SEIYAKU 243
Business Overview 243
Leading Products 244
Hyalein 244
Cravit/Oftaquix 244
Corporate Strategy 244
CHAPTER EIGHT: CNS: NEXT-GENERATION MECHANISMS OF
ACTION 245
TABLE 117 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY
DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 245
CNS: NEXT-GENERATION MECHANISMS …CONTINUED) 246
KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM
MARKET 247
2009 FDA PEDIATRIC ADVISORY COMMITTEE ON
PRESCRIPTION OF ANTIPSYCHOTICS 247
GROWTH SEEN VIA PURSUIT OF ADDITIONAL
INDICATIONS VERSUS NCE APPROVALS 247
ALZHEIMER'S DRUGS IN JAPAN OPEN UP LARGE
OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS 248
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 248
TABLE 118 RECENTLY APPROVED AND PIPELINE FORECAST,
2009-2015 ($ MILLIONS) 248
MARKET TRENDS 249
OVERALL MARKET FLAT: HIGHER MIX OF GENERICS
OFFSET BY HIGHER VOLUME 249
SIGNIFICANT IMPACT OF PATIENT ADVOCACY GROUPS
IN CNS DISEASE 249
GROWTH SEEN VIA PURSUIT OF ADDITIONAL
INDICATIONS VERSUS NCE APPROVALS 249
IMPROVING PERFORMANCE IN DEPRESSION
TREATMENTS 250
ALZHEIMER'S THERAPY CONTINUES TO RECEIVE LARGE
AND IMPORTANT INVESTMENT 250
TABLE 119 PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM
DRUGS, 2010 AND 2015 ($ MILLIONS) 251
TABLE 120 MARKET SHARE BY LEADING CENTRAL NERVOUS
SYSTEM PLAYERS, 2010 ($ MILLIONS/%) 251
TABLE 120 (CONTINUED) 252
TABLE 121 LARGEST REVENUE GENERATING THERAPIES IN THE
CENTRAL NERVOUS SYSTEM DISEASE, THROUGH 2010 ($
MILLIONS) 252
CHAPTER NINE: MARKETS BY DISEASE 253
SUMMARY OF MARKET DYNAMICS 253
TABLE 122 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY
DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 254
PSYCHIATRY 254
MARKET DYNAMICS 254
Market Dynamics (Continued) 255
TABLE 123 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 ($
MILLIONS) 255
TABLE 123 (CONTINUED) 256
DEPRESSION 256
Market Dynamics 256
TABLE 124 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($
MILLIONS) 257
Generic Drug Trends: Depression 257
TABLE 125 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($
MILLIONS) 257
TABLE 125 (CONTINUED) 258
MULTIPLE SCLEROSIS AND PARKINSON'S 258
MARKET DYNAMICS 258
TABLE 126 GLOBAL MS AND PARKINSON'S MARKET THROUGH
2010 ($ MILLIONS) 259
GENERIC DRUG TRENDS: PARKINSON'S 259
TABLE 127 GLOBAL MS AND PARKINSON'S MARKET, THROUGH
2015 ($ MILLIONS) 260
EPILEPSY/CONVULSIONS 260
MARKET DYNAMICS 260
TABLE 128 GLOBAL EPILEPSY MARKET, THROUGH 2010 ($
MILLIONS) 261
TABLE 129 GLOBAL EPILEPSY MARKET, THROUGH 2015 ($
MILLIONS) 261
GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS 262
ALZHEIMER'S 262
MARKET DYNAMICS 262
TABLE 130 GLOBAL ALZHEIMER'S MARKET, THROUGH 2010 ($
MILLIONS) 263
TABLE 131 GLOBAL ALZHEIMER'S MARKET, THROUGH 2015 ($
MILLIONS) 263
TABLE 131 (CONTINUED) 264
GENERIC DRUG TRENDS: ALZHEIMER'S 264
ADHD AND NARCOLEPSY 264
MARKET DYNAMICS 264
TABLE 132 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2010
($ MILLIONS) 265
TABLE 133 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015
($ MILLIONS) 265
GENERIC DRUG TRENDS: ADHD/NARCOLEPSY 266
MIGRAINE AND OTHER CNS DISEASE 266
MARKET DYNAMICS 266
TABLE 134 GLOBAL MIGRAINE MARKET, THROUGH 2015 ($
MILLIONS) 266
TABLE 135 GLOBAL OTHER CENTRAL NERVOUS SYSTEM
MARKET, THROUGH 2015 ($ MILLIONS) 267
PIPELINE ANALYSIS 267
TABLE 136 APPROVED PRODUCT FORECAST, 2009-2015 ($
MILLIONS) 268
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 268
KEY TRENDS IN RESEARCH AND DEVELOPMENT 268
SNRIs Improve the Baseline Performance of Leading
Depression Therapies 268
New Products Provide Larger Opportunities Compared to
Product Extensions 269
Combination Products Yield Greater Therapeutic
Response 269
Alzheimer's Therapy Continues to Receive Large and
Important Investment 269
KEY PRODUCTS UNDER MAJOR CNS DISORDERS 270
Schizophrenia 270
Depression 270
Alzheimer's 271
Parkinson's Disease 272
Epilepsy 272
Insomnia 272
Attention Deficit Hyperactivity Disorder 272
Other Indications 273
2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY 273
PHASE III AND PENDING APPROVAL COMPOUNDS 273
TABLE 137 BAPINEUZUMAB (AAB–001): ELAN/WYETH/PFIZER 273
Phase III and Pending … (Continued) 274
TABLE 138 TELCAGEPANT (MK–0974): MERCK 275
Phase III and Pending … (Continued) 276
TABLE 139 SOLANEZUMAB (LY2062430): ELI LILLY 277
TABLE 140 SEMAGACESTAT (LY450139): ELI LILLY 278
TABLE 141 VILAZODONE: CLINICAL DATA 279
RECENTLY APPROVED/MARKETED DRUGS 280
TABLE 142 STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE):
DAINIPPON SUMITOMO (FORMERLY SEPRACOR) 280
TABLE 143 INTUNIV (GUANFACINE): SHIRE 281
TABLE 144 TREXIMET (SUMATRIPTAN AND NAPROXEN):
GSK/POZEN 282
TABLE 145 PRISTIQ (DESVENLAFAXINE): PFIZER/WYETH 283
Recently Approved/… (Continued) 284
TABLE 146 VIMPAT (LACOSAMIDE): UCB/SCHWARZ PHARMA 285
TABLE 147 DEVELOPMENTAL PRODUCT FORECAST 2009-2015 ($
MILLIONS) 286
CHAPTER TEN: COMPANY PROFILES 287
SUMMARY 287
COMPANIES 287
ABBOTT LABORATORIES 287
Business Overview 287
Therapeutic Areas 288
TABLE 148 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 288
Corporate Strategy 288
ALLERGAN, INC 288
Business Overview 288
Therapeutic Areas 289
TABLE 149 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 289
Corporate Strategy 289
ASTELLAS PHARMA, INC 289
Business Overview 289
Therapeutic Areas 289
TABLE 150 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 290
Corporate Strategy 290
ASTRAZENECA 290
Business Overview 290
Therapeutic Areas 291
TABLE 151 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 291
Corporate Strategy 291
BAYER AG 292
Business Overview 292
Therapeutic Areas 292
TABLE 152 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 293
Corporate Strategy 293
BIOGEN IDEC (FUMAPHARM AG) 293
Business Overview 293
Therapeutic Areas 293
TABLE 153 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 294
Corporate Strategy 294
ELI LILLY & CO 294
Business Overview 294
Therapeutic Areas 294
TABLE 154 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 295
Corporate Strategy 295
FOREST LABORATORIES, INC 295
Business Overview 296
Therapeutic Areas 296
TABLE 155 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 296
Corporate Strategy 296
GLAXOSMITHKLINE (GSK) 297
Business Overview 297
Therapeutic Areas 297
TABLE 156 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 297
Corporate Strategy 297
JOHNSON & JOHNSON 298
Business Overview 298
Therapeutic Areas 298
TABLE 157 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 298
Corporate Strategy 299
MERCK & CO, INC 299
Business Overview 299
Therapeutic Areas 300
TABLE 158 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 300
Corporate Strategy 300
NOVARTIS AG (NOVARTIS PHARMACEUTICALS) 300
Business Overview 300
Therapeutic Areas 301
TABLE 159 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 301
Corporate Strategy 301
PFIZER, INC 301
Business Overview 302
Therapeutic Areas 302
TABLE 160 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 302
Corporate Strategy 302
SANOFI-AVENTIS 303
Business Overview 303
Therapeutic Areas 303
TABLE 161 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 304
Corporate Strategy 304
SHIRE PHARMACEUTICALS GROUP, PLC 304
Business Overview 304
Therapeutic Areas 304
TABLE 162 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 305
Corporate Strategy 305
Business Overview 305
Therapeutic Areas 306
TABLE 163 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 306
Corporate Strategy 306
TEVA PHARMACEUTICAL INDUSTRIES LTD 306
Business Overview 306
Therapeutic Areas 307
TABLE 164 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 307
Corporate Strategy 307
WATSON PHARMACEUTICALS, INC 307
Business Overview 308
Therapeutic Areas 308
TABLE 165 LEADING PRODUCTS AND REVENUE, 2009 ($
MILLIONS) 308
Corporate Strategy 308
CHAPTER ELEVEN: CANCER TRENDS: EVOLVING THERAPIES 309
INTRODUCTION 309
TRENDS IN ONCOLOGY DRUG DEVELOPMENT 309
PERSONLIZED TREATMENTS BECOMING STANDARD OF
CARE 309
VACCINES IMPROVE ACCESS TO IMMUNE RESPONSE 310
COST TO SERVE IS NEXT FRONTIER OF
DIFFERENTIATION 310
ONCOLOGISTS REPLACE DRUG COMPANIES TO DELIVER
COMBINATION THERAPY 311
TABLE 166 ONCOLOGY MARKETS BY TYPE OF THERAPY,
THROUGH 2010 ($ MILLIONS) 311
MARKET ANALYSIS BY DRUG CLASS 311
KEY RECENT EVENTS IN THE CANCER MARKET 312
FDA WITHDRAWS BREAST CANCER INDICATION FOR
AVASTIN 312
MYLOTARG WITHDRAWN BASED ON BOTH SAFETY AND
EFFICACY CONCERNS 312
JEVTANA APPROVED FOR METASTATIC HORMONEREFRACTORY
PROSTATE CANCER 313
STIMUVAX PHASE III TRIALS RESUMED BY MERCK
SERONO 313
FDA CONTINUES GARDASIL REVIEW 314
NEOPLASIA THERAPY 314
COMPETITIVE DYNAMICS OF NEOPLASIA THERAPY 314
TABLE 167 ONCOLOGY MARKETS BY DRUG CLASS, THROUGH 2010
($ MILLIONS) 315
LEADING NEOPLASIA THERAPY BRANDS 316
TOTAL NEOPLASIA THERAPY MARKET 316
TABLE 168 2010 ONCOLOGY MARKETS BY LARGEST
THERAPEUTIC DRUGS, THROUGH 2010 ($ MILLIONS) 316
NEOPLASIA THERAPY MAB MARKET ANALYSIS 317
MARKET DYNAMICS 317
PRODUCT REVIEW 317
Erbitux (Cetuximab) 317
Nexavar (Sorafenib) 318
NEOPLASIA THERAPY PROTEIN KINASE INHIBITORS 319
MARKET DYNAMICS
To order this report:
Drug and Medication Industry: Markets for Emerging Pharmaceutical Technologies
Drug and Medication Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
